|
| | Erdosteine Basic information |
| | Erdosteine Chemical Properties |
| Melting point | 156-160°C | | Boiling point | 590.4±50.0 °C(Predicted) | | density | 1.48±0.1 g/cm3(Predicted) | | storage temp. | Sealed in dry,2-8°C | | solubility | Acetonitrile (Slightly), DMSO (Slightly), Methanol (Slightly) | | form | Solid | | pka | 3.71(at 25℃) | | color | White to Off-White | | λmax | 236nm(H2O)(lit.) | | Merck | 14,3647 | | InChIKey | QGFORSXNKQLDNO-UHFFFAOYSA-N | | CAS DataBase Reference | 84611-23-4(CAS DataBase Reference) |
| RTECS | AJ1476200 | | HS Code | 2934.99.9001 | | Toxicity | LD50 in mice and rats (g/kg): >10 orally; >3.5 i.v. (Gonella) |
| | Erdosteine Usage And Synthesis |
| Description | Erdosteine is a new expectorant introduced in France for the treatment
of chronic bronchitis. Erdosteine possesses mucomodulator, mucolytic, mucokinetic
and free radical scavenging properties. Its therapeutic efficacy has been
demonstrated in patients affected by congestion and viscous mucus in higher and lower
respiratory tracts as in acute and chronic bronchitis, sinusitis, otitis,
tracheopharyngitis and coryza. Erdosteine acts through its active metabolites
containing free sulfhydryl groups which are able to depolymerize the
mucopolysaccharides of the excreatum by breaking the disulfide linkages (thereby
lowing its viscosity). The prodrug approach provides unique characteristics to
erdosteine by offering stable therapeutic efficacy and prevention of the gastric mucus
from lythic phenomena. The agent was also reported to have local antiinflammatory and
antielastase properties and enhances penetration of antibiotics into bronchial mucus. | | Description | Erdosteine is a mucolytic agent and an antioxidant. It inhibits LPS-induced IκB kinase (IKK) activity, NF-κB-mediated transcription, and production of IL-6 and IL-1β in RAW 264.7 cells. Erdosteine (7.5 mg/kg) prevents depletion of renal catalase and glutathione peroxidase (GPX) and increases in renal malondialdehyde (MDA) and nitric oxide (NO) levels in a rat model of nephrotoxicity induced by cisplatin . It reduces spinal cord lipid peroxidation and destruction of spinal motor neurons in a rabbit model of spinal cord ischemia and reperfusion injury induced by thoracoabdominal aortic clamping. Erdosteine (150 mg/kg) reduces lung weight, MDA and protein carbonyl levels, and macrophage and neutrophil accumulation in a mouse model of acute lung injury induced by oleic acid (Item Nos. 90260 | 24659). Formulations containing erdosteine have been used in the treatment of chronic obstructive pulmonary disease (COPD). | | Chemical Properties | Off-White Solid | | Originator | Refarmed (Switzerland) | | Uses | A mucolytic, developed for the treatment of chronic obstructive bronchitis. | | Uses | Erdosteine is a mucolytic. Erdosteine was developed for the treatment of chronic obstructive bronchitis. | | Definition | ChEBI: Erdosteine is a N-acyl-amino acid. | | Brand name | Edirel; Vectrine |
| | Erdosteine Preparation Products And Raw materials |
|
